ASCO 2025 | A new-generation risk-adapted prognostic index in smoldering and multiple myeloma

There is an ongoing revolution in multiple myeloma in terms of diagnosis and treatment. And particularly in our institution, we are going to evaluate all consecutive patients coming to us with the new generation molecular evaluation according to SKY92 panel combined with a series of multiomic assays. The objective of this study that we have presented here at ASCO 2024 is to detect new biomarkers, biomarkers of response, biomarkers of in some way activity for different drugs, and the idea to perform a targeted therapy in multiple myeloma. Because in this moment we have many drugs, many combinations, but we don’t have a targeted driven approach. We have seen inside our study that potentially we can develop biomarkers of risk in the smoldering myeloma and biomarkers of response to different drugs in newly diagnosed and relapsed/refractory myeloma. We have in this moment collected results from our mono-institutional study, but we want to extend this data to a national network in order to improve the importance of the data and in order to our dream is to develop a score, a prognostic score that will in some way integrate molecular data in order to improve and to optimize the treatments that we have available in multiple myeloma. These data are going to be combined with the imaging data of whole body MRI plus PET-CT that we have presented in other study here at ASCO 2025 in order to show the best in terms of optimizing the diagnostic tool that we have available. All this to optimize the use of the drug and to run to the cure of multiple myeloma which is the best wish that we give to our patients, to all their caregivers and to all myeloma researchers. Thank you for the attention.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.